Manufacturers report positive data for motixafortide in stem-cell mobilisation for autologous bone marrow transplantation in multiple myeloma

In the GENESIS phase 3 study (n=122) this short synthetic peptide, when given in conjunction with G-CSF improved the rate of stem cell mobilisation vs GCSF alone (70.0% vs 14.3% achieved mobilised ≥ 6 million CD34+ cells/kg in up to two apheresis sessions, p<0.0001).

Source:

Biospace Inc.